Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why can’t they raise prices as therapeutics comes online to levels that are still acceptable to payers (especially if duration Pam’s out saving md visits etc) and then just provide coupons to spas etc and take a modest hot to aesthetics share (but maintain especially if duration pans out for a certain percentage of patients )
The key questions we should ask are whether the initial blew up is a 4 billions plus mistake?
And whether that causes permanent damage to Daxxify potential.
For me, it’s golden opportunity BUT I got suck in a lot higher
That’s the bullish way of looking at it. They blew their best chance. Now it’s crawling their way back and TBD how long it’ll take.
Good point. I think both reorder revenue and number of reorder accounts are important
If reorder account is great but revenue is low, it also could mean issues
It’s actually not a bad thing if your shorting stats are correct.
Usually this means a much faster re-rate when good news finally hit.
We have couple good news that can hit any time
I bought into Bluebio Jan ‘24.
Some of these are just buy and holds.
Viking is another one with promise.
You've just explained the "CosmeticMD effect." Keeping patients away from the best product on the market for reasons that have nothing to do with the product. That can only go on for so long.
Not easy to get those burned accounts back. Last Q conf call talked about that. And it’s a small community so word gets around. Even the ones that didn’t get burned know the ones that did and dont like how things played out.
Every morning the shorts sell between 14,000 and 30,000 shares at the open in an effort to drive the price down. Yesterday, 62% of the shares traded were shorts. The shorts will continue to drive the price down day after day as long as Mark Foley keeps his head up Angus Russell's butt. Mark Foley has NOT made a positive announcement is almost 12 months...All Foley does is announces how he is fixing his previous bad decisions which he did not realize where being made....Mark Foley's strategy is to SUPRISE the investment community with sales info and completely lacks any communication skills...that is why Investors have lost trust in him and continue to see Foley a a lose cannon! Rather than provide positive announcements on development (like Evolus and manage the investment community) Mark Foley has this "ego edge" which is why RVNC was arrogant and obnoxious! Where is the announcement for the new indication for Lips for RH3...Lips are now the #1 dermal filler injection area.....Allergan would be all over this new indication with press releases....Foley has his head up his butt. Dew, Foley is a trainwreck!
Jessica most likely left because she could not take the bad decisions of Foley!
Friday Flash Sale!
https://www.instagram.com/reel/C5Vy_0WrDSW/?igsh=dWdtaWZyZmtweXp2
Remember how Mark Z was hated when Meta was going below $100...everyone said he was crazy and stupid. Can't build any product.
Now, Meta is at all time high. Guess what. Mark Z is still the CEO there. And now, people praise him like God-sent.
Price drives sentiment sometimes.
Q4 - more than 2/3 of the revenue was from reorders.
"our growth will come from a combination of new account adds, along with ongoing reorders. And as we noted in Q4, more than 2/3 of our revenue came from reordering accounts, which I think points to the stickiness of the product in those accounts where we’re able to secure. So we feel very good about where we are"
Why buy @ $4.50 now when you could have bought for $15.00 just six months ago?! 🙃
Foley is not the problem. Better days are ahead. Control what you can control and leave the rest.
lol you guys need to chill out about Foley.
If he is doing what you are suggesting and doing so so obviously , he would be out by now. He owns lots of shares here too.
No one in their right mind would pay 100mm to buy the secondary if Foley is so useless
Foley is not the only problem anymore. He’s brought a whole new crop of people who don’t know a thing about this business or how to turn it around. Not going to get better anytime soon because even if he is replaced his bad hires are not going anywhere.
Interesting observations. Cant stop sellers from getting out at all cost though. I picked up some more shares today. Once the liquidation is done, stock will ramp back up. Fundamentally, the company is going to get stronger over next few quarters.
They are just starting to scratch the surface.
Ask yourself this - would you pay $4.5 a share for $RVNC led by Foley. Foley isn't going away.
Agreed. Foley is not to blame for all of Revance's problem. Overcoming the "CosmeticMD effect" was always going to be a challenge—particularly with a product that requires some intelligence to use properly. We'll see what happens in therapeutics where doctors are motivated to give their patients the best results rather than to lie to them to pad their own pockets.
Well, Evolus took their fair beating too back in the day. Went from high 20s to $3/sh and people made fun of David, the Allergan salesman with no CEO experience. Foley on the other hand sold his old business to Allergan for 2.5B. Foley made terrible decisions but he eventually corrects them. Did I vote to remove him via BOD? Yes, but that probably wont matter. Remember, both Evolus and Revence raised equity via stock offering days apart.
I agree. I'm waiting for RVNC to hit $2 or Foley to be exited to buy more shares. I've made a lot of money over the years on RVNC and have a negative trade-adjusted cost basis. This may be another big opportunity—but I want more potential reward for taking on that risk, or for the risk (Foley) to be removed.
Mark Foley's bad decisions and dishonesty in every area seems to be the central theme of RVNC. Great products (Daxi and RHA) and FAILED Foley leadership. The investment community realizes it is only a matter of time until Foley will make more bad decisions since he has no idea what he is doing. David Moatazedi worked for Allergan for many years and knows what works, what Allergan failed at and how to bring a product to market in a competitive environment. Mark Foley on the other hand, never worked in toxins, never brought a product to market in a completive environment and always claims he does not know what is going on. Which I am now coming to the realization, that he really did not know and still have no clue. As long as Foley leads, the SP will continue to drop. Blind leading the sheep... Maybe Foley makes the decision to wait a full year, to release Daxi for CD...needs 4 full cycles...RVNC needs LEADERSHIP!
It's interesting that RVNC has attracted such intense attention from perpetual losers like CosmeticMD. What motivates the voraciousness of his lies about Daxxify? It takes a very sad and pathetic type of person to come onto an investing board to lie about being short the stock and lie about the product—unless of course that person has financial motivation to do so. It looks to me like some people are pretty afraid of Daxxify's potential.
I was not suggesting they promote off label at all. Rather run trials and get a label for frontalis, or if that is too costly (money and time), at least get more data and publish it where injectors can learn what differences if any there might be for daxi in these other areas of the face
The presumption I am sure was that all these muscles (at least in the face) are comparable and it would not be worth the money and time to run them, but there was a hint that daxi may perform differently in different muscle groups from the CD trial where you didn't need double the botox dose for efficacy
again hindsight is 20/20 but they were dealing with a fundamentally new drug unlike evolus which is basically a botox biosimilar
I expect Q1 to be very weak. The consumer is obviously retrenching. Ironically this should help Daxxify sales since it's a better value to the patient than Botox—but unfortunately Daxxify still has a premium price attached to it by many injectors.
Interest rates are also likely to stay higher this year than many anticipated at the start of the year. Revance's challenged balance sheet and recent surprise dilution will keep RVNC hyper-sensitive to interest rates for the foreseeable future.
Taken together I wouldn't be surprised if we see RVNC at $2 in the next few months. Insolvency is definitely a growing risk especially if Foley keeps making mistakes but there are still many levers that can be pulled to avoid that.
All of that said, Daxxify is clearly the best toxin on the market. There's only so long that the mediocre CosmeticMDs can hide that from their patients. Even if another long acting toxin comes to market Daxxify should be able to take significant market share from Botox and the other lesser toxins. If Daxxify sales establish a solid growth trend then RVNC's share price will recover.
Just picked up some more shares
It’s mind boggling that shares trade at 1/10 of the high after approval all because of a mess up rollout.
And the secondary is down 30 percent already without any news
Current expectations for q1 is 53 to 59mm.
I think q3 and q4 would be the ones we should focus on anyways
Always a good day when the stock market goes up and RVNC just stays the same! Mark
Foley is doing an amazing job! I am sure all of you saw the Corporate announcement for the New Lip Indications for RH3! What a great job Foley is doing communicating to the Investor community....Wall Street believes Foley. And the new Lip Indication for RHA3 is from the FDA....not something which Foley is just making up in his head!
In hindsight not fleshing out the proper dosing and technique for other areas of the face was also a mistake - it sounds like many injectors knew what to do for glabella but not frontalis, lateral canthal, etc. which affected results
That though should get sorted out through real world experience over time
Ulta Beauty: Consumers are seeing pressure from too much credit card debt at high interest rates. ULTA also said that there are mixed data points around the economic situation for the majority of consumers. The company noted that it has seen a slowdown in demand across beauty categories.
It’s not updated. She’s gone as of last week.
>> I post when I have something to say.
Good point. There is really no news after the secondary... except the share price has been dropping like a rock.
Jessica Serra is listed as the IR contact on the Revance website.
I see your points and do not disagree with you.
Followers
|
151
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
7611
|
Created
|
02/09/14
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |